Davis R M Inc. Has $47.89 Million Stock Position in Stryker Co. (NYSE:SYK)

Davis R M Inc. raised its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 133,017 shares of the medical technology company's stock after purchasing an additional 9,057 shares during the period. Davis R M Inc.'s holdings in Stryker were worth $47,893,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. Independent Advisor Alliance raised its stake in Stryker by 19.4% during the fourth quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company's stock worth $2,934,000 after acquiring an additional 1,325 shares during the period. Paragon Private Wealth Management LLC grew its stake in Stryker by 12.6% during the 4th quarter. Paragon Private Wealth Management LLC now owns 1,258 shares of the medical technology company's stock worth $453,000 after buying an additional 141 shares during the last quarter. Johnson Investment Counsel Inc. increased its position in Stryker by 6.5% in the fourth quarter. Johnson Investment Counsel Inc. now owns 176,956 shares of the medical technology company's stock worth $63,713,000 after buying an additional 10,856 shares during the period. Daiwa Securities Group Inc. boosted its holdings in shares of Stryker by 5.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 51,886 shares of the medical technology company's stock valued at $18,682,000 after acquiring an additional 2,883 shares during the period. Finally, NBT Bank N A NY increased its holdings in shares of Stryker by 20.1% in the 4th quarter. NBT Bank N A NY now owns 4,240 shares of the medical technology company's stock worth $1,527,000 after acquiring an additional 709 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several research analysts have commented on SYK shares. JPMorgan Chase & Co. upped their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Barclays boosted their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Citigroup reaffirmed a "buy" rating and issued a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Finally, Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $421.90.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Trading Down 0.1 %

Shares of SYK traded down $0.38 on Wednesday, reaching $364.92. 979,092 shares of the company's stock were exchanged, compared to its average volume of 1,214,331. The business has a 50 day moving average price of $382.70 and a two-hundred day moving average price of $373.40. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market capitalization of $139.24 billion, a P/E ratio of 46.98, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm earned $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker's dividend payout ratio is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.